Analytical Data
-
Gene name
Chemotaxis inhibitory
- Application
-
Alternative Names
SLC9A1BP; Calcineurin homologous protein; Calcineurin B-like protein; EF-hand calcium-binding domain-containing protein p22
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q99653
-
Expression Region
Gly2~His195
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Chemotaxis inhibitory protein (Chips) is a critical protein that plays a significant role in modulating the immune response, particularly in the context of infections and inflammation. Originally identified in the context of bacterial pathogenesis, Chips are known to inhibit the movement (chemotaxis) of immune cells towards the site of infection by interfering with chemokine signaling pathways. This action can be both beneficial and detrimental; while it may prevent excessive inflammation and tissue damage during an infection, it can also hinder effective immune responses, allowing pathogens to persist. Recent studies have highlighted the potential of recombinant Chips as therapeutic agents in managing inflammatory diseases and promoting better immune regulation. By understanding the structure-function relationship of these proteins, researchers aim to develop targeted therapies that could enhance immune responses to infections or modulate inflammation in autoimmune conditions. Additionally, the applications of recombinant technology in producing these proteins have opened new avenues for drug development and interventions in immune-related disorders, making the study of Chemotaxis inhibitory proteins a rapidly expanding field with promising implications for clinical therapeutics.
